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Abstract
Stromal interaction molecule 1 (STIM1) and the ORAI1 calcium channel mediate store-operated calcium entry (SOCE) and 
regulate a multitude of cellular functions. The identity and function of these proteins in thyroid cancer remain elusive. We 
show that STIM1 and ORAI1 expression is elevated in thyroid cancer cell lines, compared to primary thyroid cells. Knock-
down of STIM1 or ORAI1 attenuated SOCE, reduced invasion, and the expression of promigratory sphingosine 1-phosphate 
and vascular endothelial growth factor-2 receptors in thyroid cancer ML-1 cells. Cell proliferation was attenuated in these 
knock-down cells due to increased G1 phase of the cell cycle and enhanced expression of cyclin-dependent kinase inhibitory 
proteins p21 and p27. STIM1 protein was upregulated in thyroid cancer tissue, compared to normal tissue. Downregula-
tion of STIM1 restored expression of thyroid stimulating hormone receptor, thyroid specific proteins and increased iodine 
uptake. STIM1 knockdown ML-1 cells were more susceptible to chemotherapeutic drugs, and significantly reduced tumor 
growth in Zebrafish. Furthermore, STIM1-siRNA-loaded mesoporous polydopamine nanoparticles attenuated invasion and 
proliferation of ML-1 cells. Taken together, our data suggest that STIM1 is a potential diagnostic and therapeutic target for 
treatment of thyroid cancer.
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Introduction
Thyroid cancer is the most prevalent endocrine cancer, the 
incidence and related mortality of which are increasing 
globally [1]. 95% of thyroid cancer forms arise from folli-
cular cells [2, 3]. Usually, the prognosis of thyroid tumors 
is good. However, due to dedifferentiation or genetic muta-
tions, highly aggressive phenotypes arise, which potenti-
ate metastasis of tumor cells mainly to lungs, brain and 
bones, causing death of the patient within 6 months [4, 
5]. There is no rational treatment available for such tumors 
[6]. Thus, novel approaches to curtail and halt the progres-
sion of thyroid cancer to a metastatic and terminally fatal 
disease are urgently warranted.
Store-operated calcium entry (SOCE) is activated as a 
result of agonist-evoked emptying of calcium stores in the 
endoplasmic reticulum (ER). This mechanism results in 
activation of plasma membrane calcium channels and cal-
cium entry into the cells, ensuring that the calcium stores 
will be replenished [7]. The calcium signals generated 
by the SOCE regulate a multitude of cellular functions, 
including cancer cell proliferation, invasion and migra-
tion [8–11].
Stromal interaction molecule 1 (STIM1) is localized 
in the ER and plasma membrane. It functions as an ER-
calcium sensor protein and gets activated by ER calcium-
depletion, oligomerizes with other STIM1 molecules, and 
recruits plasma membrane ORAI1 channels. This results 
in calcium entry into the cells and refilling of the ER-cal-
cium stores [12]. STIM1 has been shown to activate also 
other channels, e.g. transient receptor potential canonical 
(TRPC) isoforms, including TRPC1 [13]. Previously, we 
have reported that TRPC1 functions in thyroid cancer cells 
as a receptor-operated calcium channel and modulates thy-
roid cancer cell invasion [14].
Previous studies have indicated that there are relatively 
high expression levels of STIM and ORAI isoforms in 
several cancer cell types [15]. The expression and function 
of STIM1 and ORAI1 in thyroid cancer progression and 
invasion have, however, remained elusive.
In the present study, we investigated the expression 
of STIM1 and ORAI1 proteins in thyroid cells and their 
importance in regulating invasion. We report that the 
expression of STIM1 is upregulated in all thyroid cancer 
cell lines studied compared to primary thyroid cells. Nota-
bly, STIM1 was upregulated in all thyroid cancer patient 
tissue samples investigated, as compared with normal thy-
roid tissue. In thyroid follicular ML-1 cancer cells, SOCE 
was significantly decreased in both stable STIM1 (STIM1-
KD) and ORAI1 (ORAI1-KD) knock-down cells, com-
pared with control mock-transfected cells. Furthermore, 
the basal invasion was decreased, and the sphingosine 
1-phosphate (S1P)-evoked invasion was abolished in ML-1 
cells after STIM1-KD or ORAI1-KD. In STIM1-KD cells, 
proliferation was reduced and the expression of  S1P3, vas-
cular endothelial growth factor-2 (VEGFR2), and H1F-1α 
was decreased, as well as the activity of matrix metallo-
proteinase -2 and -9 (MMP2 and MMP9). In a zebrafish 
xenograft model, STIM1-KD decreased tumor growth. 
Furthermore, we show that STIM1-KD increases the sus-
ceptibility of thyroid cancer ML-1 cells to drugs used for 
treatment of thyroid cancer, reinstates the expression of 
thyroid stimulating hormone receptor (TSHR), thyroid 
specific proteins and increased iodine uptake. Finally, use 
of modified mesoporous polydopamine (MPDA) nano-
particles was found to be a useful system for functional 
delivery of siRNA in thyroid cancer cells.
Materials and methods
H6621 cell culture medium, supplements kit and gelatin-
based coating solution were purchased from Cell Biolog-
ics (Chicago, IL, USA). DMEM, sodium pyruvate solu-
tion, BSA, fatty acid-free BSA, poly-l-lysine, puromycin, 
HEPES solution and JumpStart Taq DNA polymerase were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
RPMI 1640 medium (without l-glutamine) was from Lonza 
(Basel, Switzerland). FBS, trypsin–EDTA solution, l-glu-
tamine, penicillin/streptomycin (P/S), OptiMEM, and F-12 
(Ham’s nutrient medium) GIBCO™, RevertAid reverse tran-
scriptase, RiboLock RNase inhibitor, random hexamer prim-
ers, dNTPs, GeneRuler 100-bp Plus DNA Ladder, HEPES, 
the bicinchoninic acid protein assay reagent kit Pierce™ and 
Alexa Fluor™ Red Fluorescent Control siRNA were from 
Thermo Fisher Scientific (Waltham, MA, USA). Sphingo-
sine 1-phosphate (S1P) was from Biomol (Plymouth, PA). 
Primary antibodies against  S1P1,  S1P3, TG, NIS, TPO, and 
Hsc70 were from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). HRP-conjugated goat anti-rabbit IgG and the 
Aurum total RNA isolation kit were from Bio-Rad (Her-
cules, CA, USA). Primary antibodies against VEGFR2, 
HIF-1α, p21waf1/cip1, p27kip1, cdk6, MMP2, ERK1/2, 
pERK1/2, E-cad, N-Cad, TSHR, and HRP-conjugated anti-
rat and anti-mouse IgG were from Cell Signaling Technol-
ogy (Denver, MA, USA). Primary antibody against STIM1, 
ORAI1, and calpain activity and MTT proliferation assay 
kits were purchased from Abcam (Cambridge, MA). Cell 
culture plastic ware and human collagen type IV were from 
Becton Dickinson (Franklin Lakes, NJ, USA), and Tran-
swell inserts for invasion assays were from Corning, Inc. 
(Corning, NY). All the chemicals and reagents used were 
of molecular biology and reagent grades. Fura-2 AM was 
from Molecular Probes (Eugene, OR). Thapsigargin was 
from Alexis Corporation (San Diego, CA). KAPA Probe 
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Fast Master Mix was from Kapa Biosystems (Boston, MA), 
and the Universal Probe Library probes were from Roche 
(Basel Switzerland).
Cell culture
Human primary thyroid epithelial cells were purchased 
from Cell Biologics (Chicago, IL, USA). The cells were 
cultured in complete human epithelial cell medium with 
supplements kit (H6621, cell biologics, Chicago, IL, USA). 
The cells were plated on gelatin-coated plates as per manu-
facturer’s instructions. The human ML-1 follicular thyroid 
cancer cells were cultured in DMEM with 10% FBS, 1% 
penicillin/streptomycin (P/S), and 1% L-glutamine. FTC-133 
thyroid follicular cancer cells were purchased from Banca 
Biologica e Cell Factory (Genova, Italy). The cells were cul-
tured in DMEM and F-12 (Ham’s) medium (1:1) with 10% 
FBS and 1% L-glutamine and 1% P/S. The C643 anaplastic 
thyroid cancer cells were provided by Dr Nils-Erik Heldin 
(Karolinska Institute, Stockholm, Sweden) and cultured in 
DMEM with 10% FBS, 1% L-glutamine, and 1% penicil-
lin/streptomycin. The anaplastic thyroid cancer THJ-16T 
cells were acquired from Dr John Copland (Mayo Clinic, 
FL, USA). The cells were cultured in RPMI 1640 with 10% 
FBS, 1% penicillin/streptomycin, 1 mM sodium pyruvate, 
and 25.03 mM HEPES. The cell cultures were maintained 
in a water saturated atmosphere supplemented by 5% CO2 
and 95% air at 37 °C in the incubators.
Generation of stable cell lines
Cells were grown on 12-well plates. The transduction was 
performed according to the manufacturer’s instructions 
using non-targeting shRNA lentivirus particles, and STIM1- 
or ORAI1-targeting lentiviral particles (Sigma, St. Louis, 
MO, USA). The sequences are provided in Supplementary 
Table 1. After 48 h, the medium was changed to medium 
containing 0.5 µg/ml Puromycin. The cells were cultured 
with puromycin-containing medium hereafter. The knock-
down of STIM1 and ORAI1 was measured on mRNA level 
by quantitative-PCR and on protein level by western blot-
ting, respectively.
Transient transfections
4 million cells were pelleted and re-suspended in 400 µl 
OptiMEM together with 20 µg of the control siRNA, siS-
TIM1, pYFP, pSTIM1 or pORAI1 plasmids. The cells were 
electroporated at 975 µF and 240 V and were grown in 
respective media for 48 h before the start of the experiments.
Qualitative end‑point PCR and quantitative realtime 
PCR
RNA was extracted with Aurum™ Total RNA Mini Kit 
(Bio-Rad; CA, USA) or by TRI reagent (Sigma Aldrich; 
St. Louis, MO, USA) according to the manufacturer’s 
instructions. RNA integrity was checked by gel electropho-
resis and RNA concentration and purity was determined 
with Nanodrop 2000 (Thermo Fisher Scientific; Waltham, 
MA) and NanoVue Plus (Healthcare Bio-Sciences AB; 
Uppsala, SE). cDNA samples were prepared with Rever-
tAid reverse transcriptase and SuperScript  IV® Reverse 
Transcriptase (Thermo Fisher Scientific, MA, USA) from 
equal amounts of RNA. Reaction mixtures lacking either 
reverse transcriptase or RNA were used as negative con-
trols. For primers information see supplementary Table 1. 
Quantitative real-time PCR assays were designed with 
the Universal Probe Library (UPL) Assay Design Center 
(www. roche appli edsci ence. com). PBGD was used as a ref-
erence gene. RT-PCR was performed with KAPA Probe 
Fast Master Mix and the StepOnePlus Real-Time PCR 
System (Applied Biosystems™, Thermo fisher scientific, 
MA, USA) using the relative standard curve method.
Western blotting
The whole cell lysates and for the Western blotting were 
performed as described elsewhere [16]. In some experi-
ments, equal amounts of proteins were loaded on 10% Fast 
Cast Stain-free sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels. Blotting was per-
formed using PVDF membranes using a BioRad Transblot 
system. After blocking, the blots were probed overnight 
with primary antibodies. Proteins were detected with 
enhanced chemiluminescence (ECL; Thermo Scientific, 
242 Waltham, MA). Densitometric analysis was performed 
using the ImageJ program for image analysis (National 
Institutes of Health, Bethesda, MD), and the results were 
corrected for protein loading by normalization with Hsc70 
expression.
Measurements of  [Ca2+]i in single cells
Cells were processed and analyzed as described elsewhere 
[17]. A HAMAMATSU digital camera C10600 ORCA-R2 
with controller (Photonics K.K.) was used to capture fluo-
rescence images at 1–3 s to avoid bleaching. The images 
were acquired and processed using the Axon Imaging Work-
bench 6 software (INDEC BioSystems, Santa Clara, CA). 
The intracellular free calcium concentrations were calcu-
lated as the ratio  F340/380.
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Invasion assays
The invasion assays were performed as described else-
where [18]. Cells were serum starved by growing in 0.2% 
FAF-BSA-containing serum-free medium (SFM) overnight 
before the start of the invasion assays. In these experiments, 
the cells were stimulated with S1P and allowed to migrate 
towards 10% lipid-stripped FBS (LS-FBS) for 16 h. In other 
experiments, cells were allowed to invade towards 10% FBS-
containing culture medium for 16 h. The non-migrated cells 
were removed with a cotton swab. The migrated cells were 
fixed in 2% paraformaldehyde for 10 min and then stained 
with 0.1% crystal violet in 20% methanol for 5 min. The 
membranes were washed with PBS and water and allowed to 
dry overnight. The cells were counted at 40X magnification 
in a straight line bisecting the membrane.
Zymography
ML-1 MOCK and STIM1-KD cells were grown on 35-mm 
plates up to 80% confluency. The medium was changed 
to SFM medium for overnight incubation. Next day, the 
medium was changed to fresh SFM medium (1 ml on each 
plate) and the cells were stimulated with or without S1P 
(100 nM) for 6 h. After 6 h, the media were collected. 
Equal volumes of medium were mixed with loading buffer 
(0.1 m Tris–phosphate buffer, pH 6.8, containing 20% glyc-
erol, 6% SDS, and 0.04% bromphenol blue). The samples 
were electrophoresed with the 10% SDS gels containing 
gelatin (2.65 mg/ml). The gels were incubated in Zymo 
buffer (50 mm Tris–HCl containing 2.5% Tween 80 and 0.02 
 NaN3, pH 7.5) for 30 min. The gels were then incubated 
in Zymo buffer containing 1 μm  ZnCl2 and 5 mm  CaCl2 
for 30 min. For gelatinolytic activity gels were incubated at 
37 °C for overnight in buffer containing 50 mm Tris–HCl, 
5 mM  CaCl2, 1 μm  ZnCl2, and 0.02%  NaN3 (pH 7.5). The 
gelatin degradation was visualized under UV light, and after 
that, the gels were stained with Coomassie Blue R250 for 
1–2 h. The gelatinolytic activity was visualized as clear 
bands against blue background on stained gels. The clear 
bands, after destaining for 30 min as shown in (Fig. 5E), 
were quantified by the program ImageJ. The data were nor-
malized with the respective total protein concentrations of 
the respective cells in the culture plates.
Calpain activity assays
2 million cells were grown on 100-mm plates. The cells were 
serum-starved overnight and stimulated with or without S1P 
(100 nM) for 6 h. Next, the cells were detached and washed 
three times with PBS. Thereafter, calpain activity assays 
were performed according to the manufacturer’s instructions 
(Abcam, Cambridge, MA). The samples were analyzed at 
an excitation of 400 nm and emission at 505 nm using a 
fluorescence analyzer. The results were normalized with the 
respective total protein concentrations of each culture plate 
and presented as % calpain activity.
Proliferation assays
The [3H] thymidine incorporation method was used to 
study the proliferation of the ML-1 MOCK, STIM1-KD and 
ORAI1-KD cells. 50,000 cells were seeded on 35-mm plates 
and allowed to grow for 24 h. Four hours prior to the end 
of each experiment, 0.4 μCi/ml  [3H]thymidine was added. 
The cells were washed three times with PBS, incubated for 
10 min with 5% trichloric acetic acid, and then incubated for 
10 min with 0.1 m NaOH. The samples were transferred into 
scintillation tubes and high sample load scintillation cock-
tail Optiphase Hisafe 3 was added. The radioactivity was 
measured using a Wallac 1414 liquid scintillation counter.
MTT proliferation assay method 10,000
ML-1 MOCK and STIM1-KD cells were grown on 96 well 
plate for overnight and treated with indicated concentra-
tion of respective drugs for 24 h. Thereafter, the assays 
were performed according to the manufacturer’s instruc-
tions. The absorbances were measured at 590 nm using a 
spectrophotometer.
FACS analysis
0.5 million ML-1 Mock, STIM1-KD and ORAI1-KD cells 
were grown overnight on 35-mm plates. The cells were 
detached with EDTA-trypsin solution and were centri-
fuged. The cell pellets were suspended in 500 μl of pro-
pidium iodide solution (0.05  mg/ml propidium iodide, 
3.8 μM sodium citrate, 0.1% Triton X-100 in PBS) and incu-
bated for 15 min at room temperature. The samples were 
then processed by flow cytometry using FACSCalibur and 
CellQuest Pro software (BD Biosciences, San Jose, CA). 
ModFit LT 4.1 software was used to calculate the percentage 
of cells in each phase of cell cycle.
Fig. 1  Expression of STIM1 and ORAI1 proteins and generation of 
stable knock-down cells. A Expression profile of STIM1 and ORAI1 
proteins in primary thyroid and aggressive thyroid cancer cell lines 
by western blotting. The bars show the mean ± SEM (n = 3, *P < 0.05, 
**P < 0.01; ***P < 0.001). B-E, expression of STIM1 or ORAI1 in 
shRNA expressing (MOCK) and shRNA STIM1 expressing (STIM1-
KD) or shRNA ORAI1 expressing (ORAI1-KD) cells on mRNA and 
protein levels by RT-PCR and Western blotting, respectively. The 
bars show the mean ± S.E. (n = 3). ***p < 0.001
◂
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Iodine uptake assays
The uptake of iodide in ML-1 MOCK and STIM1-KD cells 
was determined by a nonradioactive, fast and highly repro-
ducible spectrophotometric method based on the catalytic 
effect of iodide on reduction of yellow cerium (IV) to color-
less cerium (III) in the presence of arsenious acid (Sand-
ell-kolthoff reaction). The assay was performed exactly as 
described elsewhere [19]. In some experiments, the cells 
were pre-incubated with 1 mU/ml TSH for overnight before 
the start of the assay.
Fig. 2  A Representative traces showing Thapsigargin-evoked (Tg, 
final concentration, 1 μM) changes in  [Ca2+]i in MOCK and STIM1-
KD cells in calcium-free buffer and the effect of re-addition of 1 mM 
calcium (final concentration).B Bar diagram showing the magnitude 
of the Tg-evoked peak in  [Ca2+]i. The bars show the mean ± S.E. of 
at least 40 cells. p < 0.01. C Bar diagram showing the magnitude of 
the change in  [Ca2+]i after re-addition of calcium (final concentration, 
1 mM) to Tg-treated cells. The bars show the mean ± S.E. of at least 
40 cells. ***p < 0.001. D Representative traces showing Tg-evoked 
(final concentration, 1 μM) changes in  [Ca2+]i in MOCK and ORAI1-
KD cells in calcium-free buffer and the effect of readdition of 1 mM 
calcium. E Bar diagram showing the magnitude of the Tg-evoked 
peak in  [Ca2+]i. The bars show the mean ± S.E. of at least 40 cells. F 
Bar diagram showing the area under the Tg curve (time, 60–480 s). 
The  bars  show the mean ± S.E. of at least 40 cells. G Bar diagram 
showing the magnitude of the change in  [Ca2+]i after readdition of 
calcium (final concentration, 1  mM) to Tg-treated cells. The bars 
show the mean ± S.E. of at least 40 cells. ***p < 0.001
◂
Fig. 3  STIM1 or ORAI1 knock-down attenuates invasion and recep-
tor expression in thyroid cancer ML-1 cells. A, D, STIM1 or ORAI1 
knock-down both decreased the basal and abolished the S1P-evoked 
(final concentration, 100 nm) invasion in ML-1 cells. The bars show 
the mean ± S.E. (n = 4). *Denotes comparison with MOCK cells. 
***p < 0.001. B STIM1 knock-down decreased the relative expres-
sion of  S1P3. A representative Western blot is shown. The bar dia-
gram shows the decreased expression of  S1P3 in STIM1-KD cells 
compared with MOCK cells (mean ± S.E., n = 3) ***p < 0.001. C 
STIM1 knock-down decreased the relative expression of VEGFR2. 
A representative Western blot is shown. The bar diagram shows the 
decreased expression of VEGFR2 in STIM1-KD cells compared 
with MOCK cells (mean ± S.E., n = 3). ***p < 0.001. E ORAI1 
knock-down decreased the relative expression of  S1P1. A representa-
tive Western blot is shown. The bar diagram shows the decreased 
expression of  S1P1 in ORAI1-KD cells compared with MOCK cells 
(mean ± S.E., n = 3). ***p < 0.001. F ORAI1 knock-down decreased 
the relative expression of VEGFR2. A representative Western blot is 
shown. The bar diagram shows the decreased expression of VEGFR2 
in STIM1-KD cells compared with MOCK cells (mean ± S.E., n = 3). 
***p < 0.001
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Synthesis and modification of MPDA
The mesoporous polydopamine (MPDA) particles were 
prepared by a templated synthesis method as described 
elsewhere [20]. The surface of the obtained MPDA nano-
particles were modified by N,N-dimethylethylenediamine 
(DMEA) presenting a tertiary amine group for facilitating 
the siRNA loading [21]. 1 mg of MPDA nanoparticles were 
suspended in 2 ml of Tris buffer (pH.8.5). After the introduc-
tion of DMEA (25.6 mg), the mixture was stirred for 1 h at 
room temperature. The DMEA modified MPDA nanopar-
ticles were isolated from the suspension by centrifugation.
siRNA loading of DMEA modified MPDA 
nanoparticles
0.1 mg siRNA STIM1, non-target control siRNA or con-
trol siRNA-Alexa Fluro 555 were mixed with 1 mg DMEA 
modified MPDA in 1 ml of 2-(N-morpholino) ethanesul-
fonic acid (MES) buffer (final concentration 10 mM, pH 5.0) 
through continuous vibration mixing for 40 min. The siRNA 
loaded DMEA modified MPDA nanoparticles were sepa-
rated by centrifugation at 11 000 rpm for 15 min and stored 
at − 20 °C. 50,000 ML-1 cells were grown on polylysine 
coated glass bottom 35 mm plate for overnight. Next day, 
5 µM control siRNA loaded or siRNA STIM1 loaded nano-
particles were added to respective culture plates. The cells 
were grown for 96 h to 120 h. The cells were washed, and 
the coverslips were mounted with DAPI containing mount-
ing media ProLong™ Gold Antifade mountant with DAPI. 
The laser scanning confocal microscopy was performed 
using a Leica TCS SP8 X microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) with 63 × oil immersion magni-
fication and a HC PL APO CS2 objective.
Zebrafish embryo xenograft
The procedure to carry-out xenotransplantation in zebrafish 
embryos was modified from as described elsewhere [22, 
23]. Adult zebrafish (Danio rerio, casper strain (roy−/−; 
mitfa−/−) [24] were maintained according to standard 
procedures [25]. The embryos were collected after natural 
spawning in breeding tanks. Experimentation with zebrafish 
was performed under license ESAVI/9339/04.10. 07/2016. 
The zebrafish embryos were cultured in E3-medium (5 mM 
NaCl, 0.17 mM KCl, 0.33 mM  CaCl2, 0.33 mM  MgSO4) 
supplemented with 0.2 mM phenylthiourea (PTU, Sigma-
Aldrich) at 33 °C. Two days post-fertilization, the embryos 
were anesthetized with MS-222 (200 mg/l, Sigma-Aldrich) 
and mounted into low-melting point agarose for tumor 
transplantation.
Prior to transplantation, ML-1 cells were labelled with 
5 µM CellTracker Green CMFDA (Thermofisher Scientific), 
trypsinized and washed with PBS. Approximately 5–10 nl 
of ML-1 cell suspension was microinjected into yolk of 
the embryo using CellTramVario (Eppendorf), Injectman 
Ni2 (Eppendorf) micromanipulator and self-made borosili-
cate glass needles pulled from glass capillaries (TW100-4, 
World Precision Instruments Ltd., Sarasota, FL, USA) using 
a micropipette puller (PB-7, Narishige, Tokyo, Japan). After 
injections, the agarose gel was broken and embryos were 
released, washed with E3 and cultured in E3-PTU at 33 °C. 
On 1 day post-injection (1 dpi), the successfully xenografted 
healthy embryos were selected to the experiment and placed 
into 12-well or 96-well plates (1 embryo per well). The 
embryos were anesthesized and imaged at 1 dpi and 4 dpi 
using a Zeiss AxioZoom fluorescence stereomicroscope of 
Nikon Eclipse widefield microscope.
The size of the tumor was determined by manually meas-
uring the fluorescent tumor area using FIJI software (ImageJ 
version 1.49 k) [26]. Samples having significant malforma-
tions, died embryos and images where embryo was not 
laterally oriented or out-of-focus were excluded from the 
analysis. Samples were not blinded.
Whole‑mount immunofluorescence staining 
of zebrafish embryos
Embryos were fixed for 2 h at room temperature with 4% 
PFA in PBSTw (PBS + 0.2% Tween-20). The embryos were 
rinsed twice with PBSTw after fixation and premeabilized 
for 3 h with 2 percent Triton X-100 in PBS. After permea-
bilization, the embryos were blocked in blocking solution 
(PBSTw + 5% fetal calf serum) for overnight at + 4C. After 
blocking, the embryos were incubated with primary antibody 
(anti-Cleaved Caspase-3, #9664S, Cell Signaling Technol-
ogy or anti-ki67, ab15580, Abcam) in blocking solution over 
night at + 4C. This was followed by 4 × 30 min washes with 
PBSTw and by subsequent incubation in secondary antibody 
(Alexa 568 donkey anti-rabbit, Invitrogen) in blocking solu-
tion for overnight at + 4C. Then samples were washed for 
3 h at room temperature with PBSTw and mounted in 100% 
glycerol for imaging. The sample tubes were gently rotated 
throughout the staining process.
Images were captured using Leica SP5 matrix confocal 
microscope with 20x/0.7 air objective, 2 × zooming, 600 Hz 
scanning speed and 515 × 512 pixel image settings. Line 
averaging (value 3) and frame accumulation (value 3) were 
used while acquiring images. The acquired images were 
processed using FIJI software. Fluorescence images were 
subjected to filtering with Gaussian blur filter (radius 1) and 
to background removal (rolling ball radius 50). Finally, the 
brightness and contrast were linearly adjusted, and all com-
pared samples were processed with similar settings. Tumor 
area was outlined with segmented line tool, and mean inten-
sity on Cleaved Caspase 3 or ki67 channel was measured. 
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Statistical analysis was carried out using Graph Pad Prism 
6.05 software and nonparametric Mann–Whitney U-test. 
These experiments with whole-mount zebrafish xenografts 
were performed under license ESAVI/31414/2020.
STIM1 staining of patient samples
The use of tissue samples and related data was approved 
by Auria Biobank (decision AB19-2988) and the Hospital 
District of Southwest Finland and Turku University Hospital 
(decision T12/011/20), and accordingly informed consent 
was obtained from all human participants. The samples were 
from both female and male patients (9 anaplastic thyroid 
carcinoma, 29 follicular thyroid carcinoma, and 138 papil-
lary thyroid carcinoma). The age distribution of the patients 
was 18–88 years of age. Thyroid tissue was prepared accord-
ing to standard histology practice, using buffered formalin 
(pH 7.0) for fixation and embedding tissue into paraffin 
blocks. Tissue microarrays (TMAs) were prepared from 
tumour area of each patient. As controls, normal thyroid 
tissue samples (control) were obtained from 104 patients. 
Tissue sections were cut and stained with anti-STIM1 
antibody (1/200; Abcam 57,834) using Labvision Auto-
stainer (Thermo-Fisher Scientific, Fremont, CA, USA) and 
detected with an Orion 2 step detection system using goat 
anti mouse/rabbit HRP + WellMed T100 HRP. Final images 
were acquired at 20X magnification using the case viewer 
software (HISTECH Ltd, Hungary).
High throughput data mining and Gene expression 
analyses
The clinical and transcriptomic data of the Thyroid Car-
cinoma (THCA) cohort were downloaded from the GDC 
database (https:// portal. gdc. cancer. gov/ proje cts/ TCGA- 
THCA). We included 502 thyroid tumors and 58 adjacent 
normal samples for transcriptome analysis. Among those 
tumor samples, 353 were papillary thyroid tumors while 
106 were follicular thyroid tumors. To assess gene expres-
sion levels in normal thyroid samples, we retrieved gene 
expression data (as raw count values) of 563 thyroid samples 
from the Genotype-Tissue Expression (GTEx) (https:// gtexp 
ortal. org/ home) for comparative analysis of gene expression. 
Only genes that express in at least 50% of the samples were 
assessed. DESeq2 was used for differential expression analy-
sis between thyroid cancer groups and their matched para-
cancerous samples [27]. A Benjamini–Hochberg adjusted 
p value of < 0.05 was considered as statistical significance. 
The expression profiles of genes of interest (STIM1 and 
ORAI1) were also extracted from both retrieved datasets 
after performing variance stabilizing (VST) transformation 
for comparative analyses between cancerous tissues, cancer 
adjacent normal tissues, and controls.
Statistical analysis
The results are presented as means ± the standard error of 
the mean from at least three independent measurements. 
Student’s t test was used when two means were compared. 
One-way analysis of variance and Bonferroni’s post hoc tests 
were applied when three or more means were compared. 
Kruskal–Wallis test, Kolmogorov–Smirnov test and Fisher 
exact test were used to analyze non-normally distributed 
data. GraphPad Prism 8 program (GraphPad Software Inc., 
San Diego, CA) was used for the statistical analyses. p val-
ues < 0.05 were considered statistically significant.
Results
The expression of STIM1 and ORAI1 channels 
is increased in thyroid cancer cell lines
Increasing evidence suggest that store-operated calcium 
entry (SOCE), mediated by the STIM1 and ORAI1 proteins, 
is a key player in regulating the pathophysiology of cancer 
[28, 29]. However, the expression and function of these key 
signaling proteins in human thyroid cancer has remained 
elusive. We show here that the protein level of STIM1 is 
higher in human follicular and anaplastic cancer cell lines, 
and that ORAI1 is higher in follicular cancer cell lines, com-
pared with normal human thyroid primary cells (Fig. 1A). 
Based on these results, we then investigated the importance 
of the STIM1 and ORAI1 channels in follicular thyroid can-
cer ML-1 cells, a cell line showing the highest expression 
of STIM1 and ORAI1 compared to normal human thyroid 
cells. We generated stable STIM1 and ORAI1 knock-down 
(STIM1-KD, ORAI1-KD) ML-1 cell lines (Fig. 1B–E).
Knock‑down of STIM1 or ORAI1 attenuates 
store‑operated calcium entry (SOCE)
Previous studies have established that STIM1 forms a com-
plex with ORAI1 channels to evoke SOCE [8, 11]. Thus, we 
first investigated this mechanism in ML-1 cells. As can be 
seen in (Fig. 2A–C), a significant difference was observed in 
both the thapsigargin (Tg)-evoked calcium transient and on 
 Ca2+ entry when  Ca2+ was re-added to Tg-treated STIM1-
KD cells, compared to the control MOCK cells. There was 
no significant difference in the Tg-evoked calcium transient 
in ORAI1-KD cells compared to MOCK cells as confirmed 
by calculating the area under the Tg-evoked calcium curve, 
as shown in (Fig. 2D–F). However, there was a significant 
decrease in  Ca2+ entry when  Ca2+ was re-added to the Tg-
treated ORAI1-KD cells, compared to the MOCK cells 
(Fig. 2D, G). Thus, both STIM1 and ORAI1 are important 
in regulating SOCE in thyroid cancer cells.
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Knock‑down of STIM1 or ORAI1 decrease invasion 
and receptor expression in thyroid cancer ML‑1 cells
STIM1 and ORAI1 have been reported to regulate invasion 
of cancer cells [29, 30]. We have previously characterized 
sphingosine 1-phosphate (S1P) and VEGFR2 signaling in 
thyroid cancer cells. S1P activates invasion of ML-1 can-
cer cells via the promigratory receptors S1P1, S1P3 and 
VEGFR2 [16, 31]. Thus, we investigated the effects of 
STIM1 or ORAI1 knock-down on ML-1 cancer cell inva-
sion. As can be seen in (Fig. 3A, D), both basal and S1P-
evoked invasion was attenuated in both the STIM1-KD and 
ORAI1-KD cells, compared with MOCK cells. Interestingly, 
the re-expression of STIM1 in STIM1-KD cells significantly 
restored the basal and S1P-evoked invasion, compared to 
MOCK cells. Likewise, re-expressing ORAI1 in ORAI1-KD 
cells significantly restored the basal and S1P-evoked inva-
sion (supplementary Fig. 1A and B). To further explain this 
abolished effect of S1P on STIM1-KD and ORAI1-KD cells, 
we determined S1P and VEGFR2 receptors expression. The 
results showed that S1P3 and VEGFR2 were downregulated 
in STIM1-KD cells (Fig. 3B, C). In ORAI1-KD cells, S1P1 
and VEGFR2 were downregulated (Fig. 3E, F). Thus, both 
STIM1 and ORAI1 are important regulators of thyroid can-
cer cell invasion.
Knock‑down of STIM1 and ORAI1 modulate ML‑1 cell 
proliferation
Evidence have shown that STIM1 and ORAI1 regulate 
proliferation in different cancers, including brain, ovarian, 
pancreatic, nasopharyngeal, and renal cancers [32]. We next 
investigated the effect of STIM1 and ORAI1 knock-down on 
ML-1 cell proliferation. The results show that the prolifera-
tion was significantly attenuated in both STIM1 and ORAI1 
knock-down cells, compared with MOCK cells (Fig. 4A). 
The re-expression of STIM1 in STIM1-KD cells and ORAI1 
in ORAI1-KD cells significantly restored the proliferation, 
compared to MOCK cells (Supplementary Fig. 1C). We next 
investigated the mechanism by which STIM1 or ORAI1 
knock-down cells decreased proliferation. We first analyzed 
the cell cycle by FACS analysis. In both STIM1-KD and 
ORAI1-KD cells, there was a significant increase in cell 
population in the  G1 phase, and a significant decrease in 
the S phase of the cell cycle, compared with MOCK cells 
(Fig. 4B, C). We also investigated the expression of the 
cell cycle regulatory proteins  p21kip1and  p27waf1/cip1, and 
observed that these proteins were significantly increased in 
the knock-down cells (Fig. 4D, E). Furthermore, cdk6 was 
significantly decreased in both STIM1-KD and ORAI1-KD 
cells, compared with MOCK cells (Fig. 4E).
As we observed a decrease in proliferation in STIM1-KD 
cells, we further examined if the effect of the chemothera-
peutic drugs Lenvatinib, paclitaxel and doxorubicin on the 
proliferation of MOCK and STIM1-KD ML-1 cells. These 
drugs attenuated proliferation in a concentration-dependent 
manner, and the effect was enhanced in STIM1-KD cells 
(Fig. 4F–H). This is an important observation that suggests 
a novel approach to design the treatment of thyroid cancer 
with these drugs.
STIM1 knock‑down affects the migratory signaling 
pathway, EMT markers and thyroid specific proteins
Previously, we have shown that HIF1α is downregulated in 
TRPC1 knock-down cells [14]. As can be seen in Fig. 5A, 
HIF1α expression was significantly downregulated in 
STIM1-KD cells. Next, we investigated the effects of 
STIM1-KD on epithelial mesenchymal transition (EMT) 
marker proteins. We found an upregulation of E-Cadherin 
protein and a decrease in vimentin and N-Cadherin in 
STIM1-KD cells, compared to the MOCK ML-1 cells 
(Fig. 5B). In addition, the expression of total ERK1/2 and 
phospho-ERK1/2 were downregulated (Fig. 5C). Recently, 
we have reported that S1P increased calpain activity and 
the activity of MMP2 and MMP9 through  S1P1,3, and that 
knock-down of TRPC1 decreased the secretion and activ-
ity of both MMP2 and MMP9 in ML-1 cells [14, 33]. In 
STIM1-KD cells, the basal calpain activity, and the activ-
ity of MMP2 and MMP9 were significantly decreased. 
Furthermore, the S1P-evoked increase in both calpain 
activity and the activity of MMP2 and MMP9 was abol-
ished (Fig. 5D, E). This, in part, explains the decreased 
invasion of STIM1-KD cells.
Thyroid-specific genes, including thyroid-stimulating 
hormone receptor (TSHR), sodium/iodide symporter 
(NIS), thyroperoxidase (TPO) and thyroglobulin (TG), 
are downregulated in thyroid cancer [34]. Therefore, we 
examined the expression of these proteins in STIM1-KD 
cells. Interestingly, these proteins were upregulated in 
STIM1-KD cells (Fig. 5F). In addition, both the basal and 
Fig. 4  STIM1 and ORAI1 regulate proliferation of thyroid cancer 
ML-1 cells. A STIM1 and ORAI1 knock-down decreased prolif-
eration after 48  h. The bar diagram shows the mean ± S.E. (n = 3). 
***p < 0.001. B, C STIM1 and ORAI1 knock-down decreased prolif-
eration by prolonging the  G1 phase and decreasing the S phases of the 
cell cycle. ***p < 0.001. *Statistically significant differences between 
the  G1 and S phases of cell cycle, respectively, in STIM1-KD and 
ORAI1-KD cells compared with the MOCK cells. D, Representa-
tive Western blots showing the upregulation of p21 and p27 in both 
STIM1 and ORAI1-KD cells. E Representative Western blot show-
ing the downregulation of cyclin-dependent kinase 6 (cdk6) in both 
STIM1 and ORAI1-KD cells. F–H Cells were treated with indicated 
concentrations of Lenvatinib, Paclitaxel or Doxorubicin and the pro-
liferation was assessed by MTT proliferation assays (24 h. The effects 
of tested drugs were significant (p < 0.001) in STIM1-KD compared 
with MOCK cells. Each data point represents the mean ± S.E. of at 
least three independent experiments
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Fig. 5  STIM1 knock-down decreased the expression of HIF-1α, cal-
pain activity and the activity of MMP2 and MMP9 and in ML-1 cells. 
A The expression of HIF-1α was significantly decreased in STIM1-
KD cells compared with MOCK cells. A representative Western blot 
is shown. B the expression of EMT marker proteins in STIM1-KD 
cells compared to the MOCK ML-1 cells. The representative Western 
blots are shown. C the expression of total-ERK and phospho-ERK 
in STIM1-KD cells compared with MOCK ML-1 cells. The repre-
sentative Western blots are shown. D STIM1 knock-down decreased 
the basal and abolished the S1P-evoked increase in calpain activity 
compared to MOCK ML-1 cells. (N = 4), *Denotes comparison with 
MOCK. *p < 0.05, **p < 0.01. E The basal and S1P evoked gelati-
nolytic activity of MMP2 and MMP9 was decreased in STIM1-KD 
cells, compared with MOCK ML-1 cells. The representative zymog-
raphy blot is shown. F STIM1 knock-down increased the expression 
of thyroid-specific proteins. The representative Western blots of at 
least three independent experiments are shown. G STIM1 knock-
down enhanced the basal and TSH-evoked iodine-uptake compared 
to in the MOCK cells. *Denotes comparison with MOCK cells; o, 
denotes comparison with control STIM1-KD cells. (n = 4) *p < 0.05, 
***p < 0.001, oop < 0.01
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Fig. 6.  Functional efficacy of MPDA-DMEA nanoparticles in ML-1 
thyroid cancer cells. A–C Confocal images of ML-1 cells with con-
trol siRNA-Alexa Fluor 555 loaded nanoparticles. A (DAPI), B 
(siRNA-Alexa Fluor 555), and C (Merge: DAPI + siRNA-Alexa Fluor 
555). The scale bar is 20 μm. The images shown are representative 
of at least three separate experiments. D Representative western blot 
showing the efficacy of siSTIM1 in ML-1 cells. E Representative 
western blot showing the efficacy of siSTIM1-loaded MPDA-DMEA 
nanoparticles in ML-1 cells. NL-siRNA denotes nanoparticles loaded 
siRNA. F, G siSTIM1-loaded nanoparticles decreased the invasion 
and proliferation of ML-1 cells. UnT, un-treated; E.Nano, empty 
MPDA-DMEA nanoparticles, siC Nano, control non-target siRNA 
loaded nanoparticles, siSTIM1 Nano, siSTIM1 loaded nanoparticles. 
*ML-1 unT vs siSTIM1 Nano, osiC Nano vs siSTIM1 Nano. The bars 
show the mean ± S.E. (n = 6). **p < 0.01; ***p < 0.001; oop < 0.01; 
ooop < 0.001
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Fig 7  Zebrafish xenograft experiments. A Representative images of 
one and four day (s) post injection (dpi) with MOCK and STIM1-KD 
cells and the increase in tumor growth. The scale bar is 1 mm. B, C 
Quantitation of tumor size and fold change tumor area. D Quantita-
tion of tumor growth. *p < 0.05; **p < 0.01; ***p < 0.001
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TSH-evoked (final concentration 1 mU/ml) iodine-uptake 
was increased in STIM1-KD cells (Fig. 5G).
MPDA‑DMEA nanoparticles, an efficient siRNA 
delivery system in ML‑1 cells
Nanoparticles have been shown to deliver siRNA or drugs 
into thyroid cancer cells precisely and effectively [35, 36]. 
Therefore, we first tested the uptake and release of control 
siRNA Alexa 555 Fluor-loaded MPDA-DMEA nanoparti-
cles in ML-1 thyroid cancer cells. These nanoparticles were 
efficiently taken up by the cells and the siRNA was released 
after 96 h (Fig. 6A-C). In other control experiments, we 
showed that transfecting with STIM1-siRNA, downregulate 
STIM1 protein in ML-1 cells (Fig. 6D). We observed the 
same effect using STIM1-siRNA loaded MPDA-DMEA 
nanoparticles (Fig. 6E). Next, we investigated the effect of 
the empty, or STIM1-siRNA loaded nanoparticles on ML-1 
cell invasion and proliferation. There was no effect of empty 
nanoparticles, however, both the invasion and proliferation 
were significantly downregulated by STIM1-siRNA loaded 
nanoparticles (Fig. 6F, G).
Zebrafish embryos with human thyroid tumor 
cells‑xenograft
To analyze the effects of STIM1 knock-down on tumor 
growth in vivo, we transplanted MOCK and STIM1-KD 
ML-1 cells into the zebrafish embryos. The embryos were 
kept in 96-well plates (1 embryo/well) to allow longitudinal 
analysis of tumor growth. STIM1-KD ML-1 cells exhibited 
strongly reduced tumor growth, also confirmed by calcu-
lating the tumor area and fold change (Fig. 7A–D). Taken 
together, these data indicate STIM-1 is required for full 
tumorigenic potential of ML-1-cells. Furthermore, to dis-
criminate between a halt in the proliferation versus increased 
apoptosis upon STIM1 knockdown, we used anti-activated 
Caspase 3 antibody immunofluorescence staining of MOCK 
and STIM1-KD xenografts. The results showed that the Cas-
pase 3 signal was significantly higher in STIM1-KD xeno-
graft cells compared to the MOCK xenograft cells (Sup-
plementary Fig. 2. A, B). These findings conclude that the 
STIM1 knockdown significantly induce apoptosis in ML-1 
xenograft cells.
In addition, to confirm that the quantified CellTracker 
Green signal in zebrafish xenografts is coming from living 
human thyroid tumor cells, we performed human specific 
Ki67 antibody immunofluorescence staining. The results 
showed that the CellTracker Green signal was originating 
from human thyroid tumor living cells. The quantification 
of Ki67 antibody signal in MOCK xenograft tumor was sig-
nificantly higher compared to in STIM1-KD xenograft tumor 
(Supplementary Fig. 2. C, D). These findings conclude 
that the MOCK xenograft cells are dividing actively while 
STM1-KD xenograft cells are not proliferating efficiently 
which in part is due to induction of apoptosis.
Analysis of STIM1 and ORAI1 gene and protein 
expression in human thyroid
Expression of STIM1 in normal and thyroid cancer patient 
samples
A higher expression of STIM1 has been suggested to corre-
late with poor prognosis and survival in many cancers [37]. 
We investigated the expression of STIM1 in thyroid cancer 
patient samples and obtained 176 thyroid cancer patient tis-
sue samples and 104 normal thyroid tissue samples (normal 
tissue of the same thyroid cancer patient, as well as normal 
thyroid tissue from healthy subjects) as described in the 
method section. The results showed an increased STIM1 
staining in all types of thyroid cancer patient samples, com-
pared to respective patient’s normal thyroid tissue adjacent 
to the tumor, or with healthy subjects’ normal thyroid tissue 
sections (Fig. 8A–G).
Differential gene expression in thyroid cancer 
versus normal thyroid tissues
STIM1 and ORAI1 gene expression was evaluated in thyroid 
tumor tissues (n = 502) versus normal thyroid solid tissues 
(n = 58) datasets in the TCGA Thyroid Carcinoma cohort. 
The expression of both STIM1 and ORAI1 genes was sig-
nificantly upregulated in both the papillary and combined 
thyroid cancer tissues (Total), compared to tumor adjacent 
normal thyroid tissues (NT). However, we found STIM1 bor-
derline upregulated (p = 0.058) but not ORAI1 in follicular 
thyroid cancer tissues (Fig. 8H). Furthermore, a comparison 
of STIM1 expression in normal thyroid solid tissues (GTEX 
dataset), thyroid tumor tissues (TP) and tumor adjacent nor-
mal thyroid tissues (NT) was determined. Interestingly, we 
observed that STIM1 was significantly upregulated not only 
in thyroid tumor tissues (TP) but also in the tumor adjacent 
thyroid tissues (NT), compared to the normal thyroid tis-
sues (GTEX) (Fig. 8I). In another comparison, we found 
the STIM1 expression was significantly higher in follicular 
thyroid cancer tissues compared to the papillary thyroid can-
cer tissues (Fig. 8J).
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Discussion
The hallmarks of cancer include uncontrolled growth, and 
invasion of the cancer cells [38, 39]. For these processes 
calcium and calcium channels have been shown to play 
important roles [11, 40, 41]. We have previously shown that 
calcium entry is important for the invasion and proliferation 
of follicular thyroid cancer ML-1 cells [14]. The STIM- and 
ORAI proteins have also been considered as novel targets 
for cancer therapy [15, 32]. We show here that, especially 
STIM1, but to some extent also ORAI1, are upregulated 
in several thyroid cancers cell lines, compared with nor-
mal thyroid cells. This has also been shown in e.g. ther-
apy resistant ovarian cancer cell lines [42]. Furthermore, 
STIM1 was upregulated in all studied patient samples of 
papillary, follicular, and anaplastic thyroid cancer, compared 
with healthy thyroid tissues from the same patients or from 
normal healthy subjects. Similar results have been obtained 
in several other cancers, including cervical cancer [43], 
melanoma [44], and colorectal cancer [45]. The differential 
STIM1 and ORAI1 gene expression analysis data clearly 
showed an upregulation of these genes in most of the thyroid 
cancer tissues compared to normal thyroid tissues datasets. 
Surprisingly, an increased STIM1 gene expression but not 
ORAI1 was observed in the tumor adjacent normal tissue, 
compared to the normal thyroid tissue, indicating a possible 
role of STIM1 in the initiation of thyroid tumor formation. A 
higher STIM1 expression in follicular thyroid cancer tissues 
compared to the papillary thyroid cancer tissues datasets 
further suggests that STIM1 is important in the development 
of an aggressive thyroid cancer phenotype.
Downregulation of STIM1 or ORAI1 efficiently attenu-
ated both proliferation and invasion of ML-1 cells, decreased 
the expression of cdk6 and increased the expression of 
the cell cycle regulators p21 and p27. In cervical cancer, 
inhibition of STIM1 resulted in increased expression of p21, 
and arrested the cells in the S- and G2/M phase of the cell 
cycle [43]. In our experiments STIM1-KD and ORAI1-KD 
halted cells in the G1 and S phase. This was also observed 
in TRPC1-KD ML-1 cells [14]. We next investigated the 
effects of STIM1-KD in Zebrafish embryos [46, 47]. By 
injecting control ML-1 cells in the zebrafish xenograft 
experiments, the cells grew into a clear tumor; however, the 
STIM1-KD cells were unable to evoke tumor growth. This 
experiment shows that also in an in vivo setting, STIM1-KD 
cells were unable to proliferate and form a tumor.
In addition to basal invasion, STIM1 and ORAI1 knock 
down cells reduced the S1P-evoked invasion. As shown pre-
viously, S1P is an important enhancer of cancer cell inva-
sion [48], including thyroid cancer cells [16]. In both knock 
down cell lines, the expression of VEGFR2 was decreased, 
whereas SIP3 was decreased in STIM1-KD cells, and S1P1 
in ORAI1-KD cells. These receptors are crucial for S1P-
evoked invasion [49]. In melanoma, STIM1 blockade the 
recycling of MT1-MMP to the plasma membrane, thus 
inhibiting the breakdown of the extracellular matrix [44]. 
Furthermore, in STIM1-KD cells the S1P-stimulated extru-
sion of MMP2 and -9 was attenuated, and HIF-1α, an impor-
tant regulator of ML-1 cell invasion [50], was reduced. The 
results are in line with our previous study, showing that in 
TRPC1-KD ML-1 cells, the expression of VEGFR2, S1P3, 
MMP2 and -9, and HIF-1a were all decreased [14]. Collec-
tively these results show that calcium fluxes play a vital role 
for the regulation of factors involved in the proliferation and 
invasion of thyroid cancer cells.
In addition to surgery, pharmacological interventions are 
important in treating thyroid cancer [51]. We show that three 
commonly used drug, i.e., lenvatinib, paclitaxel and doxoru-
bicin, efficiently attenuated proliferation of the ML-1 cells. 
Notably, the effect of these drugs was enhanced in STIM1-
KD cells. A similar observation was made in STIM1-KD 
pancreatic adenocarcinoma cells [52]. These results sug-
gest that a combination of chemotherapy and knock down 
or blocking of STIM could be effective in treating thyroid 
cancer. However, the use of pharmacological blockers or 
siRNA in the inhibition of e.g., STIM1 is problematic, con-
sidering the ubiquitous expression of this protein. To avoid 
this, nanoparticles carrying drugs or siRNA can be an option 
[53]. This has been proposed for thyroid cancer cells [35, 
54]. We have previously shown that drug-loaded nanoparti-
cles can efficiently induce apoptosis of thyroid cancer cells 
[36]. Here we show that siRNA-loaded nanoparticles can 
be used successfully to knock down STIM1, and thereby 
attenuate both proliferation and invasion of the ML-1 cells. 
A combination of siRNA-loaded nanoparticles and lower 
doses of e.g., doxorubicin could be a novel approach to cur-
tail thyroid cancer progression, with less adverse effects of 
the chemotherapy.
Fig. 8  STIM1-protein expression in human normal and thyroid can-
cer tissues. A, B Representative images of normal and papillary 
thyroid cancer. C, D Representative images of normal and follicular 
thyroid cancer tissue. E, F Representative images of normal and ana-
plastic thyroid cancer tissue. The representative images of control and 
cancer tissue sections of each cancer type are from the same patient. 
G Representative image of normal thyroid tissue from a healthy sub-
ject. Scale bar 50 µM. The final images were acquired at 20× magni-
fication using case viewer software (3DHITECH Ltd, Germany). H 
Heatmap to visualize differential expression of STIM1 and ORAI1 
between thyroid tumors and their adjacent normal samples. The color 
intensity represents log2 Fold Changes. Significances have been 
corrected by Benjamini–Hochberg method. *p < 0.05; **p < 0.01; 
***p < 0 .001. I STIM1 expression comparison between thyroid 
cancer tissues, their para-cancerous tissues, and normal controls. 
Data were presented as mean ± SE. One-way ANOVA test was used 
to assess statistical significance. ***p < 0 001. J STIM1 and ORAI1 
expression comparison between papillary thyroid cancer tissues and 
follicular thyroid cancer tissues. Data were presented as mean ± SE. 
Unpaired t test was used to assess statistical significance. **p < 0.01.
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An interesting observation was the fact that knock-
ing down STIM1 increased the TSH receptor expression. 
In rat thyroid FRTL-5 cells, knock down of TRPC2 also 
induced an increase in TSH receptor expression [17]. Fur-
ther, we observed an increased expression of the thyroid 
specific proteins thyroglobulin, thyroperoxidase, and the 
Na-I symporter in STIM1-KD cells. STIM1 knock down 
enhanced TSH-evoked uptake of iodine, decreased vimentin 
and N-cadherin expression, and elevated E-cadherin expres-
sion. Previously, knock-down of STIM1 has been shown to 
suppress the expression of proteins important for epithe-
lial-mesenchymal transition and enhance the expression of 
E-cadherin in human prostate cancer cells [55]. Our results 
thus suggest that the ML-1 cells obtained a more normal 
thyroid phenotype, with re-differentiation of the cells [56]. 
The precise mechanisms by which STIM1-KD regulates the 
expression of these proteins remain to be established. Nota-
bly, as STIM1-KD increased TSH-evoked uptake of iodine, 
the cells should be more susceptible to take up radioac-
tive iodine, which may induce apoptosis. Thus, radioactive 
iodine could be used to destroy thyroid cancer cells.
Conclusions
We have shown here using different approaches and gene 
downregulation in thyroid cancer cells that calcium sign-
aling and the STIM1 protein play an important function 
in driving thyroid cancer cell proliferation and invasion. 
Furthermore, we have shown that blocking calcium entry 
pathways by using siRNA-loaded nanoparticles effectively 
inhibit proliferation and invasion of the cells. In view of this, 
we propose that the combination of drugs and siRNA target-
ing could be a useful approach to design better treatments 
for thyroid cancer and for the benefit of patients afflicted by 
aggressive, metastatic forms of thyroid cancer.
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